Abstract/References

Successful management of pelvic recurrence of MSI-High endometrial cancer by total pelvic exenteration followed by administration of pembrolizumab:A case report

Manabu Kojima, Shu Soeda, Chikako Okabe, Tetsu Sato, Norihito Kamo, Makiko Ueda, Yuta Endo, Shinji Nomura, Emi Tokuda, Shigenori Furukawa, Masao Kataoka, Shotaro Fujita, Shigehira Saji, Takafumi Watanabe, Keiya Fujimori

Abstract

Surgery can be curative treatment for pelvic locoregional recurrence of endometrial cancer; however, a cure is contingent on complete resection. Here, we report the case of a patient in whom recurrent endometrial tumor remained in the pelvis after resection; long-term control was achieved with postoperative administration of pembrolizumab.

The patient had recurrent endometrial cancer of stage IA and was treated with chemotherapy and radiation, but tumor persisted in the pelvic cavity. We therefore attempted total pelvic exenteration, but the tumor was adherent to the pelvic wall and complete resection could not be achieved. However, postoperative administration of pembrolizumab controlled the residual tumor for more than two years without regrowth. We believe that since the resected tumor was MSI-High, the residual tumor responded well to pembrolizumab. It is not known whether cytoreductive surgery contributes to a long-term response to pembrolizumab, but at least in our patient, pembrolizumab appeared to be a very effective drug therapy for MSI-High endometrial cancer that was refractory to chemotherapy and radiotherapy.

The content of research paper

References

1. Morice P, Leary A, Creutzberg C, et al. Endometrial cancer. The Lancet 387:1094-1108, 2016.
2. Fung-Kee-Fung M, Dodge J, Elit L, et al. Follow-up after primary therapy for endometrial cancer:A systematic review. Gynecologic Oncology, 101:520-529, 2006.
3. Soeda S, Watanabe T, Nomura S, et al. Surgical management of recurrent gynecological cancer:Complete resection is the key to longer survival. European Journal of Gynaecological Oncology, 40:28-35, 2019.
4. Höckel M, Dornhöfer N. Pelvic exenteration for gynaecological tumours. Lancet Oncol, 7:837-847, 2006.
5. Papadia A, Bellati F, Ditto A, et al. Surgical Treatment of Recurrent Endometrial Cancer:Time for a Paradigm Shift. Annals of Surgical Oncology, 22:4204-4210, 2015.
6. Hoskins PJ, Swenerton KD, Pike JA, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer:A phase II study. Journal of Clinical Oncology, 19:4048-4053, 2001.
7. Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer:A systematic review of Cochrane collaboration. Annals of Oncology, 18:409-420, 2007.
8. Merck Sharp & Dohme Corp. A BREAKTHROUGH THAT MAY HELP YOU FACE YOUR CANCER. 2512, 2020.
9. Kauppila A. Oestrogen and progestin receptors as prognostic indicators in endometrial cancer:A review of the literature. Acta Oncologica, 28:561-566, 1989.
10. Chaudhry P, Asselin E. Resistance to chemotherapy and hormone therapy in endometrial cancer. Endocrine-Related Cancer, 16:363-380, 2009.
11. Del Carmen MG, Birrer M, Schorge JO. Uterine papillary serous cancer:A review of the literature. Gynecologic Oncology, 127:651-661, 2012.
12. Rauh-Hain JA, Carmen, MG. Treatment for Advanced and Recurrent Endometrial Carcinoma:Combined Modalities. The Oncologist, 15:852-861, 2010.
13. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer:Results from the phase II KEYNOTE-158 study. Journal of Clinical Oncology, 38:1-10, 2020.
14. Chan JK, Lakomy DS, McDonald Y, et al. Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer. Gynecologic Oncology Reports, 33:100581, 2020.
15. Bristow RE, Zerbe MJ, Rosenshein NB, et al. Stage IVB endometrial carcinoma:The role of cytoreductive surgery and determinants of survival. Gynecologic Oncology, 78:85-91, 2000.

Figures (2)